Unicycive Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Details) - Schedule of Outstanding Shares Potentially Dilutive Securities - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Schedule of Outstanding Shares Potentially Dilutive Securities [Line Items]
Antidilutive Securities	209,993,175	176,063,976	209,993,175	176,063,976
Options to purchase common stock [Member]
Schedule of Outstanding Shares Potentially Dilutive Securities [Line Items]
Antidilutive Securities	13,671,140	10,321,616	13,671,140	10,321,616
Warrants to purchase common stock [Member]
Schedule of Outstanding Shares Potentially Dilutive Securities [Line Items]
Antidilutive Securities	4,784,193	4,784,193	4,784,193	4,784,193
Restricted stock units [Member]
Schedule of Outstanding Shares Potentially Dilutive Securities [Line Items]
Antidilutive Securities	21,765		21,765
Common stock issuable upon conversion of Series B-2 convertible preferred stock [Member]
Schedule of Outstanding Shares Potentially Dilutive Securities [Line Items]
Antidilutive Securities	7,882,000		7,882,000
Common stock issuable upon conversion of Series A-2 Prime convertible preferred stock [Member]
Schedule of Outstanding Shares Potentially Dilutive Securities [Line Items]
Antidilutive Securities	22,676,000	43,649,000	22,676,000	43,649,000
Warrants to purchase convertible preferred stock [Member]
Schedule of Outstanding Shares Potentially Dilutive Securities [Line Items]
Antidilutive Securities	160,958,167	160,958,167	160,958,167	160,958,167